山西医药杂志
山西醫藥雜誌
산서의약잡지
SHANXI MEDICAL JOURNAL
2013年
20期
1107-1109
,共3页
胃肿瘤%癌胚抗原%逆转录聚合酶链反应%华蟾素
胃腫瘤%癌胚抗原%逆轉錄聚閤酶鏈反應%華蟾素
위종류%암배항원%역전록취합매련반응%화섬소
Stomach neoplasms%Carcinoembryonic antigen%Reverse transcriptase polymerase chain re-action%Cinobufotion
目的：分析外周血中癌胚抗原信使核糖核酸（CEA mRNA）在诊断胃癌血行转移中的应用价值，评价抗癌中药华蟾素对胃癌的疗效。方法将Ⅲb～Ⅳ期晚期胃癌患者随机分为治疗组和对照组。2组均采用口服替吉奥胶囊方案化疗2个周期，替吉奥80 mg · m-2· d-1，每天2次，于早饭后和晚饭后各服1次，连服14 d，停药7d，3周为1个周期；治疗组在化疗同时加用华蟾素注射液20mL＋5％葡萄糖注射液500mL，每日1次，连用14 d。应用反转录-聚合酶链反应技术（RT-PCR）检测患者运用药物前后外周血CEA mRNA 的含量。结果胃癌患者治疗前，治疗组CEA和CEA mRNA阳性率分别为34％、62％；对照组分别为32％、58％，2组间含量差异均无统计学意义。治疗后，对照组患者CEA 和CEA mRNA 的阳性率分别为28％、49％；治疗组分别为27％、44％（ P ＞0．05），治疗组治疗前后CEA与CEA mRNA含量差异有统计学意义（ P ＜0．05），2组间治疗后CEA含量差异无统计学意义，CEA mRNA含量差异有统计学意义（ P＜0．05）。结论 CEA mRNA的表达可能与肿瘤微转移相关，采用反转录-聚合酶链反应（RT-PCR）方法检测外周血中CEA mRNA的表达，可能是一种较理想的预测方法；抗癌中药华蟾素联合化疗用药可有效治疗胃癌。
目的：分析外週血中癌胚抗原信使覈糖覈痠（CEA mRNA）在診斷胃癌血行轉移中的應用價值，評價抗癌中藥華蟾素對胃癌的療效。方法將Ⅲb～Ⅳ期晚期胃癌患者隨機分為治療組和對照組。2組均採用口服替吉奧膠囊方案化療2箇週期，替吉奧80 mg · m-2· d-1，每天2次，于早飯後和晚飯後各服1次，連服14 d，停藥7d，3週為1箇週期；治療組在化療同時加用華蟾素註射液20mL＋5％葡萄糖註射液500mL，每日1次，連用14 d。應用反轉錄-聚閤酶鏈反應技術（RT-PCR）檢測患者運用藥物前後外週血CEA mRNA 的含量。結果胃癌患者治療前，治療組CEA和CEA mRNA暘性率分彆為34％、62％；對照組分彆為32％、58％，2組間含量差異均無統計學意義。治療後，對照組患者CEA 和CEA mRNA 的暘性率分彆為28％、49％；治療組分彆為27％、44％（ P ＞0．05），治療組治療前後CEA與CEA mRNA含量差異有統計學意義（ P ＜0．05），2組間治療後CEA含量差異無統計學意義，CEA mRNA含量差異有統計學意義（ P＜0．05）。結論 CEA mRNA的錶達可能與腫瘤微轉移相關，採用反轉錄-聚閤酶鏈反應（RT-PCR）方法檢測外週血中CEA mRNA的錶達，可能是一種較理想的預測方法；抗癌中藥華蟾素聯閤化療用藥可有效治療胃癌。
목적：분석외주혈중암배항원신사핵당핵산（CEA mRNA）재진단위암혈행전이중적응용개치，평개항암중약화섬소대위암적료효。방법장Ⅲb～Ⅳ기만기위암환자수궤분위치료조화대조조。2조균채용구복체길오효낭방안화료2개주기，체길오80 mg · m-2· d-1，매천2차，우조반후화만반후각복1차，련복14 d，정약7d，3주위1개주기；치료조재화료동시가용화섬소주사액20mL＋5％포도당주사액500mL，매일1차，련용14 d。응용반전록-취합매련반응기술（RT-PCR）검측환자운용약물전후외주혈CEA mRNA 적함량。결과위암환자치료전，치료조CEA화CEA mRNA양성솔분별위34％、62％；대조조분별위32％、58％，2조간함량차이균무통계학의의。치료후，대조조환자CEA 화CEA mRNA 적양성솔분별위28％、49％；치료조분별위27％、44％（ P ＞0．05），치료조치료전후CEA여CEA mRNA함량차이유통계학의의（ P ＜0．05），2조간치료후CEA함량차이무통계학의의，CEA mRNA함량차이유통계학의의（ P＜0．05）。결론 CEA mRNA적표체가능여종류미전이상관，채용반전록-취합매련반응（RT-PCR）방법검측외주혈중CEA mRNA적표체，가능시일충교이상적예측방법；항암중약화섬소연합화료용약가유효치료위암。
Objective To analyze the application value of peripheral blood carcinoembryonic antigen messen-ger ribonucleic acid(CEA mRNA) in the diagnosis of the hematogenous metastasis of gastric cancer ,and to evalu-ate the therapeutic effect of the anti-cancer traditional Chinese herb “Cinobufotalin” on gastric cancer .Methods Phase Ⅲb-Ⅳ stage of advanced gastric cancer patients were randomly divided into treatment group and control group .Both group were treated with 2 cycles of chemotherapy :Gimeracil and Oteracil Porassium Capsules were taken orally for 80 mg · m -1 · d-1 ,twice a day after breakfast and dinner for 14 d ,rested 7 d ,and 3 weeks as a cycle .At the same time ,Cinobufacini injection of 20 mL+5% GS 500 mL was used in the treatment group once a day for 14 days .RT-PCR was used to determine the CEA mRNA in peripheral blood before and after the adminis-tration of drugs .Results Before the therapy with“Cinobufotalin” ,the positive rates of CEA and CEA mRNA in experimental group were 34% and 62% ,respectively ,and that in control group were 32% and 58% ,respective-ly .After the therapy with“Cinobufotalin” ,the positive rates of CEA and CEA mRNA in experimental group were 28% and 49% ,respectively ,and that in control group were 27% and 44% ( P>0 .05) .A significant difference of the contents of CEA and CEA mRNA before and after the treatment was shown in the experimental group ( P<0 .05) .A significant difference of the contents of CEA mRNA after the treatment was shown between both group ( P <0 .05) ,which is contrary to the contents of CEA .Conclusion It is perhaps an ideal method to detect the micrometastasis of gastric cancer through the evaluation of expression of CEA mRNA in the peripheral blood by reverse transcription PCR (RT-PCR) .It may play an important role in the evaluation of the prognosis and the ne-cessity of adopting advanced therapy among the gastric cancer patients . Anti-cancer traditional Chinese herb“Cinobufotalin” is an effective treatment of gastric cancer.
